Osteosarcoma Collaborative, Inc.

07/15/2026

🎙️ OS Therapies Chairman, CEO and President Paul Romness joins eHealth Radio for a conversation on the company's lead immunotherapy program, OST-HER2, and the regulatory strategy supporting its development.

The interview explores the science behind the company's Listeria-based immunotherapy platform, recent Phase 2b clinical data, global regulatory pathways across the FDA, EMA and MHRA, and the path toward commercialization for patients with osteosarcoma.

Listen here: https://bit.ly/4w5GCVl

06/02/2026

OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma

75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year…...

05/13/2026

This brings hope for new European and US osteosarcoma treatment options!! I remember when the Osteosarcoma Information facebook group was up in arms that the vaccine was not being used in a human trial after a successful canine trial! Thankful for all the perseverance and hard work being done at OS Therapies!!!

OS Therapies recently hosted a biomarker-focused conference call reviewing updates across its OST-HER2 clinical and regulatory program.

The call featured strategic advisors Dr. Craig Eagle and Dr. Bob Langer, and pediatric oncology key opinion leaders Dr. Brian Ladle of Johns Hopkins and Dr. Peter Anderson of Cleveland Clinic. Discussion included:

• Biomarker and immune response findings from the Phase 2b study
• Clinical development updates in osteosarcoma
• Ongoing regulatory engagement across the U.S., Europe, U.K. and Australia
• Considerations related to confirmatory study planning and future regulatory submissions

ICYMI, view the presentation here: https://bit.ly/42O0lM1

04/29/2026

Thanks goes out to Dr Kaplan for dedicating her career to osteosarcoma research. Short read ….full of hope

When a tumor grows, its microenvironment views cancer cells not as foreign, but as injured tissue that needs to heal. This means that, unfortunately, the same healing process that repairs our normal tissue enables tumors to grow.

“A lot of cancer patients think their immune system failed them — that it did not recognize the cancer and was not able to get rid of it,” says Rosandra N. Kaplan, MD, a pediatric oncologist. “But the same features that repair us also help our tumors grow and spread.”

Dr. Kaplan and other researchers are working to illuminate key elements of cancer metastasis in order to create more effective osteosarcoma therapies.

Read more about Dr. Kaplan’s research here: osinst.org/blog/tumor-microenvironment

04/28/2026

Reminder: OS Therapies will host its OST-HER2 pharmacodynamic response biomarker conference call later this week.

Date: April 30, 2026
Time: 8:30 a.m. ET

The discussion will focus on the data supporting the OST-HER2 Immune Signature and its potential role in regulatory submissions across the U.S., Europe, and the U.K.

Register: https://bit.ly/4vYvGsC

04/09/2026

Excited to see OS Therapies continue to drive forward towards FDA approval!

OS Therapies has completed submission of Phase 2b clinical and biomarker data for OST-HER2 to the FDA in preparation for its upcoming Pre-BLA Meeting later this quarter.

This submission follows prior FDA alignment, confirming pre-specified immune biomarkers as suitable surrogate endpoints alongside the clinical outcomes data from the Phase 2b study.

Read the full details here: https://bit.ly/4v2gbQ6